Buus, Richard http://orcid.org/0000-0002-3386-3465
Szijgyarto, Zsolt
Schuster, Eugene F.
Xiao, Hui
Haynes, Ben P.
Sestak, Ivana http://orcid.org/0000-0001-6999-2851
Cuzick, Jack
Paré, Laia
Seguí, Elia
Chic, Nuria
Prat, Aleix http://orcid.org/0000-0003-2377-540X
Dowsett, Mitch http://orcid.org/0000-0003-4122-744X
Cheang, Maggie Chon U.
Funding for this research was provided by:
Breast Cancer Now
Cancer Research UK (C1491/ A15955)
Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.
Article History
Received: 3 June 2020
Accepted: 17 December 2020
First Online: 12 February 2021
Competing interests
: I.S. received lecture fees from Myriad Genetics, NanoString Technologies, and Pfizer Oncology. A.P. has uncompensated advisory role to NanoString Technologies, and received research funding from NanoString Technologies. M.C.U.C. has a patent for Breast Cancer Classifier: US Patent No. 9,631,239 with royalties paid, and receive research funding from NanoString Technologies. M.D. has provided ad hoc advice to Lilly, H3Biomedicine, AbbVie and Orion, and has been on the Scientific Advisory Board for Radius; he has received honoraria for lectures from NanoString and Myriad Genetics. J.C. is an advisor to Myriad, and his institution has received funding for statistical analyses from Genomic Health Inc., Myriad Genetics and NanoString Technologies. All other authors declare no potential competing interests.